Legal Representation
Attorney
Aaron D. Hendelman
USPTO Deadlines
Application History
12 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 15, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Apr 24, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Apr 24, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Apr 24, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 16, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Jan 16, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Oct 30, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Oct 30, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Oct 30, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Oct 18, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Sep 12, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Apr 5, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-conjugate based therapeutics, oligonucleotide-antibody conjugate based therapeutics, and oligonucleotide-antibody fragment conjugate based therapeutics for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; the foregoing featuring small interfering RNA
Class 042
Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology
Classification
International Classes
005
042
USPTO Documents
Loading USPTO documents...